Medindia

X

Anzai Validates It's Respiratory Gating Interface for IBA Proton and Particle Therapy

Wednesday, October 26, 2016 Respiratory Disease News J E 4
Advertisement

DELRAY BEACH, Fla., Oct. 25, 2016 /PRNewswire/ -- Anzai Medical Co Ltd, Japan has successfully validated the interface for its Anzai Respiratory Gating AZ-733VI product line, which controls the radiation beam for proton and particle treatment systems. The IBA gating interface validation was performed at Texas Center for Proton Therapy, Dallas, TX.

With the implementation of this interface Anzai Medical is now able to also offer Respiratory Gating to clinics that use an IBA proton therapy system. The validation confirmed the compatibility of IBA's UBTI interface for respiratory gated treatments in proton therapy.

The release includes a generic layer of hardware and software that allows Anzai to adapt the current implementation to interfaces of other proton and particle therapy vendors with minimal effort. An individual validation is required for each vendor.

The respiratory gating interface for photon therapy is already in clinical use together with Elekta linear accelerators. The first Anzai Respiratory Gating System was launched 25 years ago and has been adopted worldwide with over 1,600 units in use.

Anzai's AZ-733VI system offers the technology required to perform high-end treatment techniques within radiation therapy. Respiratory gated treatments are frequently used for special cases in which the tumor position changes throughout the respiratory cycle.

Related Images

image1.jpg

image2.jpg

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anzai-validates-its-respiratory-gating-interface-for-iba-proton-and-particle-therapy-300350924.html

SOURCE Anzai Medical Co Ltd

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Roka Bioscience to Present at the Sidoti & Company...
S
Global LASIK Treatment Market Research Report - In...